Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood- inner ear barrier in mice

Brain Research

Volumn 852, Issue 1, 2000, Pages 116-126

  Zhang, Zhi Jian ^a   Saito, Takehisa ^a   Kimura, Yuichi ^a   Sugimoto, Chizuru ^a   Ohtsubo, Toshio ^a   Saito, Hitoshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Adriamycin; Blood inner ear barrier; Mdr1a( ) mice; Ototoxicity; P glycoprotein; Vinblastine

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; VINBLASTINE SULFATE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD; CAPILLARY ENDOTHELIUM; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; EVOKED BRAIN STEM AUDITORY RESPONSE; GENE DISRUPTION; HEARING IMPAIRMENT; INNER EAR; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OTOTOXICITY; PREVENTION; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; BLOOD; CYCLOSPORINE; DEAFNESS; DOXORUBICIN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; EAR, INNER; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; P-GLYCOPROTEIN; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VINBLASTINE;

EID: 0033965014     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02223-4     Document Type: Article

References (44)

1. Arboix M., Gonzalez O., Colombo T., D'Incalci M. Multidrug resistance reversing agents increase vinblastine distribution in normal tissues expressing the p-glycoprotein but do not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Ther. 281:1997;1226-1230.
2. Barbarics E., Kronauge J.F., Cohen D., Davison A., Jones A.G., Croop J.M. Characterization of p-glycoprotein transport and inhibition in vivo. Cancer Res. 58:1998;276-282.
3. Barbui T., Rambaldi A., Parenzan L., Zucchelli M., Perico N., Remuzzi G. Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet. 339:1992;1421.
4. Beck W.T., Kuttesch J.F. Neurological symptoms associated with cyclosporin plus doxorubicin. Lancet. 340:1992;496.
5. Bigotte L., Arvidson B., Olsson Y. Cytofluorescence localization of adriamycin in the nervous system: I. Distribution of the drug in the central nervous system of normal adult mice after intravenous injection. Acta Neuropathol. 57:1982;121-129.
6. Chan S.Y., Worth R., Ochs S. Block of axoplasmic transport in vitro by vinca alkaloids. J. Neurobiol. 11:1980;251-254.
7. Chen C.-J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1a (p-glycoprotein) gene from multidrug-resistant human cells. Cell. 47:1986;381-389.
8. Cho E.S. Toxic effects of adriamycin of the ganglia of the peripherial nervous system: a neuropathological study. J. Neuropath. Exp. Neur. 36:1977;907-915.
9. Colombo T., Zucchetti M., D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J. Pharmacol. Exp. Ther. 269:1994;22-27.
10. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer D., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (p-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 86:1989;695-698.
11. Croop J.M., Raymond M., Haber D., Devault A., Arceci R.J., Gros P., Housman D.E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol. 9:1989;1346-1350.
12. Devault A., Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell. Biol. 10:1990;1652-1663.
13. Eggermont J.J., Don M. Mechanisms of central conduction time prolongation in brainstem auditory evoked potentials. Arch. Neurol. 43:1986;116-120.
14. Endicott J.A., Ling V. The biochemistry of p-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137-171.
15. Fojo A.T., Ueda K., Slamon D.J., Poplack D.J., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U. S. A. 84:1987;265-269.
16. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
17. Gros P., Ben-Neriah Y., Croop J.M., Housman D.E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 323:1986;728-831.
18. Gros P., Raymond M., Bell J., Housman D. Cloning and characterization of a second member of the mouse mdr1a gene family. Mol. Cell. Biol. 8:1988;2770-2778.
19. Hawkins E. Ototoxic mechanisms, a working hypothesis. Audiology. 12:1973;383-393.
20. Hsu S.I.H., Lothstein L., Horwitz S.B. Differential overexpression of three mdr1a gene family members in multidrug-resistant J774.2 mouse cells. J. Biol. Chem. 264:1989;12053-12062.
21. Inamura N., Salt A.N. Permeability changes of the blood-labyrinth barrier measured in vivo during experimental treatments. Hear. Res. 61:1992;12-18.
22. Jahnke K. The blood-perilymph barrier. Arch. Oto-Rhino-Laryngol. 228:1980;29-34.
23. Juhn S.K. Barrier systems in the inner ear. Acta Oto-Laryngol. (Stockholm) Suppl. 458:1988;79-83.
24. Juhn S.K., Rybak L.P. Labyrinthine barriers and cochlear homeostasis. Acta Oto-Laryngol. (Stockholm). 91:1981;529-534.
25. Juhn S.K., Rybak L.P., Fowlks W.L. Transport characteristics of the blood-perilymph barrier. Am. J. Otolaryngol. 3:1982;392-396.
26. Juhn S.K., Rybak L.P., Pardo S. Nature of blood-labyrinth barrier in experimental conditions. Ann. Otol. 90:1981;135-141.
27. Jung W.K., Gattaz G., Schön F.J. Kinetic experiments with radionuclides concerning the perilymph-blood barrier in a guinea pig model. Arch. Oto-Rhino-Laryngol. 246:1989;11-19.
28. 1 of CAP in guinea pig. Hear. Res. 53:1991;209-216.
29. Saito T., Yamada Y., Manabe Y., Yamamoto T., Saito H. Cisplatin metabolites and their toxicity on isolated cochlear outer hair cells in vitro. Acta Oto-Laryngol. (Stockholm). 116:1996;561-565.
30. Saito T., Zhang Z.-J., Tsuzuki H., Ohtsubo T., Yamada T., Yamamoto T., Saito H. Expression of p-glycoprotein in inner ear capillary endothelial cells of the guinea pig with special reference to blood-inner ear barrier. Brain Res. 767:1997;388-392.
31. Saito T., Zhang Z.-J., Yamada T., Yamamoto T., Shibamori Y., Saito H. Similar pharmacokinetics and differential ototoxicity after administration with cisplatin and transplatin in guinea pigs. Acta Oto-Laryngol. (Stockholm). 117:1997;61-65.
32. Schinkel A.H., Smit J.J.M., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A.A.M., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P.J., Berns A.J.M., Borst P. Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
33. Schinkel A.H., Wagenaar E., Mol C.A.A.M., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
34. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdr1a p-glycoprotein in mice afffects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1995;1698-1705.
35. Schweitzer V.G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 103:1993;1-52.
36. Sohmer H., Freeman S., Friedman I., Lidan D. Auditory brainstem response (ABR) latency shifts in animal models of various types of conductive and sensori-neural hearing losses. Acta Oto-Laryngol. (Stockholm). 111:1991;206-211.
37. Sonneveld P., Durie B.G.M., Lokhorst H.M., Marie J.P., Solbu G., Suciu S., Zittoun R., Lowenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet. 340:1992;255-259.
38. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K.F., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by p-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2031-2035.
39. Sziklai I., Ferrary E., Loiseau A., Sterkers O., Amiel C. Changes in the electrochemical composition of cochlear fluids after intracisternal application of doxorubicin in the rat. Eur. Arch. Otorhinolaryngol. 249:1992;149-152.
40. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84:1987;7735-7738.
41. Tran Ba Huy P., Bernard P., Schacht J. Kinetics of gentamicin uptake and release in the rat. J. Clin. Invest. 77:1986;1492-1500.
42. van Asperen J., Schinkel A.H., Beijnen J.H., Nooijen W.J., Borst P., van Tellingen O. Altered pharmacokinetics of vinblastine in mdr1a p-glycoprotein-deficient mice. J. Natl. Cancer Inst. 88:1996;994-999.
43. van Asperen J., van Tellingen O., Tijssen F., Schinkel A.H., Beijnen J.H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a p-glycoprotein. Br. J. Cancer. 79:1999;108-113.
44. Weber D.M., Dimopoulos M.A., Alexanian R. Increased neurotoxicity with VAD-cyclosporin in multiple myeloma. Lancet. 341:1993;558-559.